The global market for Lyme Disease Testing was estimated at US$12.7 Billion in 2024 and is projected to reach US$18.6 Billion by 2030, growing at a CAGR of 6.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Lyme Disease Testing market.
Segments: Technology (IGRA Testing Technology, Other Technologies); Test (Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test, Nucleic Acid Test); Sample (Blood Sample, Urine Sample, CSF Sample, Other Samples); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Other End-Uses)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Lyme Disease Testing Market - Key Trends & Drivers Summarized
Why Is Lyme Disease Testing Gaining Importance?
Lyme disease is one of the most common tick-borne illnesses, with cases rising due to climate change and increased outdoor activities in endemic areas. Early and accurate detection of Lyme disease is critical to preventing long-term complications such as neurological and joint issues. As public awareness of tick-borne diseases grows, the demand for advanced and reliable Lyme disease testing is increasing.How Are Innovations Enhancing the Performance of Lyme Disease Testing?
Advancements in molecular diagnostics, serological assays, and rapid point-of-care testing are improving the accuracy and speed of Lyme disease diagnosis. Next-generation PCR-based tests can detect the Borrelia bacteria at an early stage, reducing false negatives associated with traditional antibody tests. AI-driven diagnostic tools and at-home test kits are also emerging, providing faster and more accessible testing solutions. Additionally, researchers are developing multi-target assays that can distinguish Lyme disease from other tick-borne illnesses.What Are the Key Market Drivers?
The rising incidence of Lyme disease, increased public health initiatives, and technological advancements in diagnostic methods are key market drivers. Government agencies and research institutions are investing in better diagnostic tools to enable early detection and improve treatment outcomes. The growing trend of outdoor recreational activities and pet ownership has also heightened the need for Lyme disease awareness and testing.What Challenges and Future Opportunities Exist?
Challenges include the variability in test accuracy, high costs of advanced diagnostic methods, and limited awareness in some regions. However, opportunities exist in developing AI-assisted Lyme disease detection tools, expanding at-home test kit availability, and integrating Lyme disease screening into routine wellness check-ups.Report Scope
The report analyzes the Lyme Disease Testing market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Technology (IGRA Testing Technology, Other Technologies); Test (Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Test, Nucleic Acid Test); Sample (Blood Sample, Urine Sample, CSF Sample, Other Samples); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Other End-Uses)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the IGRA Testing Technology segment, which is expected to reach US$12.4 Billion by 2030 with a CAGR of a 5.4%. The Other Technologies segment is also set to grow at 9.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $3.3 Billion in 2024, and China, forecasted to grow at an impressive 6.5% CAGR to reach $3.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Lyme Disease Testing Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Lyme Disease Testing Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Lyme Disease Testing Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, Affymetrix, Inc., bioMérieux SA, Bio-Rad Laboratories, Inc., Ceres Nanosciences and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 32 Featured):
- Abbott Laboratories
- Affymetrix, Inc.
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Ceres Nanosciences
- DiaSorin S.p.A
- F. Hoffmann-La Roche AG
- Galaxy Diagnostics
- Gold Standard Diagnostics
- Graphene Frontiers
- IGeneX, Inc.
- LabCorp
- Meridian Bioscience, Inc.
- Oxford Immunotec
- Quest Diagnostics
- Quidel Corporation
- T2 Biosystems, Inc.
- Thermo Fisher Scientific, Inc.
- Trinity Biotech
- ZEUS Scientific
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Affymetrix, Inc.
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Ceres Nanosciences
- DiaSorin S.p.A
- F. Hoffmann-La Roche AG
- Galaxy Diagnostics
- Gold Standard Diagnostics
- Graphene Frontiers
- IGeneX, Inc.
- LabCorp
- Meridian Bioscience, Inc.
- Oxford Immunotec
- Quest Diagnostics
- Quidel Corporation
- T2 Biosystems, Inc.
- Thermo Fisher Scientific, Inc.
- Trinity Biotech
- ZEUS Scientific
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 269 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 12.7 Billion |
| Forecasted Market Value ( USD | $ 18.6 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
